Lemon Balm for Cognitive Function
The most surprising finding in the entire lemon balm literature is the Kennedy 2003 demonstration that an anxiolytic herb can simultaneously improve cognition: the highest dose tested (1600 mg of dried leaf) improved memory performance and increased calmness. In a separate 2004 trial using the Defined Intensity Stressor Simulation (DISS), a laboratory stress test, Kennedy's group found that 600 mg raised calmness and that 300 mg sped up mathematical processing with no loss of accuracy — a paradoxical "calm alert" cognitive profile distinct from every other classical anxiolytic, including the benzodiazepines and the antihistamine sedatives. The mechanism is not settled. Some lemon balm extracts inhibit acetylcholinesterase (AChE), the enzyme targeted by the prescription Alzheimer's drugs donepezil, rivastigmine, and galantamine, in the test tube, but the leaf used in the Kennedy 2003 trial showed no cholinesterase inhibition and instead bound to nicotinic and muscarinic acetylcholine receptors. The clinical translation came with the Akhondzadeh 2003 double-blind randomized controlled trial (RCT) in 42 patients with mild-to-moderate Alzheimer's disease, demonstrating modest but statistically significant improvement on ADAS-cog and CDR scales over 4 months of lemon balm extract. This page covers the cognitive trials, the AChE inhibition mechanism, the comparison to prescription cholinesterase inhibitors, and what is known about lemon balm in mild cognitive impairment and early dementia.
Table of Contents
- The Paradoxical "Calm Alert" Profile
- Kennedy 2003: Cognitive Enhancement in Healthy Volunteers
- Acetylcholinesterase Inhibition: A Proposed Mechanism
- Nicotinic and Muscarinic Receptor Binding
- Akhondzadeh 2003: Lemon Balm in Mild-to-Moderate Alzheimer's
- Lemon Balm vs Donepezil, Rivastigmine, Galantamine
- The Lamiaceae Cognitive Family (Sage, Rosemary, Spearmint)
- Mild Cognitive Impairment Applications
- Combining Lemon Balm with Conventional Care
- Dosing for Cognitive Indications
- Cautions and Drug Interactions
- Key Research Papers
- Connections
- Featured Videos
The Paradoxical "Calm Alert" Profile
Almost every anxiolytic available in clinical medicine produces some degree of cognitive impairment as a side effect. Benzodiazepines impair attention, working memory, and psychomotor speed. Sedating antihistamines (diphenhydramine, hydroxyzine) impair attention and reaction time. Alcohol impairs essentially every cognitive domain. Even the selective serotonin reuptake inhibitors (SSRIs) — not classically sedating — produce measurable processing-speed slowing in some patients. The cognitive cost is the standard trade-off for anxiety relief.
Lemon balm is the rare exception. In the Kennedy 2004 cross-over trial described in detail in Anxiety Relief (18 healthy volunteers given single doses of 300 mg and 600 mg of a standardized lemon balm extract and a placebo during the DISS stress test):
- The 600 mg dose significantly increased self-rated calmness
- The 600 mg dose reduced self-rated alertness (interpreted as physiological relaxation)
- The 300 mg dose significantly increased the speed of mathematical processing during the DISS stressor with no reduction in accuracy
In the separate Kennedy 2003 trial of dried leaf, the highest dose (1600 mg) improved memory performance and increased calmness at all postdose time points.
This is the "calm alert" profile — physiologically and subjectively calmer, but cognitively faster with no loss of accuracy, although in the 2004 trial the calming and the faster-processing results came from different doses. The combination is why lemon balm is discussed for the common situation of a person who needs to be calmer in order to perform well on a cognitively demanding task (presentation, exam, surgical procedure, important negotiation) but who cannot afford the cognitive cost of a benzodiazepine. No prescription anxiolytic reliably produces this profile.
The proposed mechanism behind the paradox combines gamma-aminobutyric acid-transaminase inhibition (raising GABAergic tone) with cholinergic effects (raising cholinergic tone): acetylcholinesterase inhibition by some extracts in the test tube, and nicotinic and muscarinic receptor binding by the leaf used in the 2003 trial. The two systems are partially complementary — GABAergic tone reduces the anxious hyperarousal that disrupts focused attention, while cholinergic tone enhances the attention itself. The result is reduced anxiety with preserved or improved cognitive performance.
Kennedy 2003: Cognitive Enhancement in Healthy Volunteers
The cognitive arm of the Kennedy 2003 trial deserves its own treatment because the cognitive findings were arguably more surprising than the anxiolytic findings. The trial was published in Neuropsychopharmacology as "Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (lemon balm) with human central nervous system (CNS) nicotinic and muscarinic receptor-binding properties."
The study first screened samples of lemon balm for human acetylcholinesterase inhibition and cholinergic receptor binding, then tested the most cholinergically active dried leaf. Twenty healthy young adults received single doses of 600, 1000 and 1600 mg of encapsulated dried leaf or a matching placebo at 7-day intervals in a cross-over format, and were tested before dosing and at 1, 3 and 6 hours afterwards. Cognitive outcome measures came from the validated Cognitive Drug Research computerized assessment battery:
- Simple reaction time
- Choice reaction time
- Digit vigilance (sustained attention)
- Numeric working memory
- Spatial working memory
- Word presentation and immediate word recall
- Delayed word recall
- Word recognition
- Picture recognition
- Self-rated alertness, contentedness, calmness (Bond-Lader scales)
The pattern of results was complex. The most notable effects were improved memory performance and increased calmness at all postdose time points for the highest (1600 mg) dose. Decrements in the speed of timed memory task performance and on a rapid visual information-processing task increased with decreasing dose, so the slowing appeared at the lower doses, not the highest. The authors concluded that doses at or above 1600 mg can improve cognitive performance and mood, and that different preparations from the same plant may behave differently depending on how the sample is prepared.
The earlier 2002 trial from the same group (Kennedy DO, Scholey AB, Tildesley NT, Perry EK, Wesnes KA, Pharmacology Biochemistry and Behavior) used a different, standardized extract in 20 healthy young adults at single doses of 300, 600 and 900 mg. It found a sustained improvement in Accuracy of Attention after 600 mg, but time- and dose-specific reductions in both Secondary Memory and Working Memory factors; self-rated calmness rose at the earliest time points with the lowest dose, while alertness was significantly reduced at all time points after the highest dose. Both nicotinic and muscarinic binding of that extract in human cortex tissue were found to be low compared with previous studies, and the 2003 paper notes that it did not exhibit in vitro cholinergic receptor-binding properties. That is why the 2003 study screened leaf samples first: its chosen leaf displaced nicotine and scopolamine from nicotinic and muscarinic receptors in human cerebral cortex tissue (IC50 0.18 and 3.47 mg/ml), the binding that gave the 2003 trial its mechanistic title. An earlier screening study (Wake 2000) had found one accession of lemon balm among the most potent European memory herbs at displacing these ligands.
Acetylcholinesterase Inhibition: A Proposed Mechanism
Acetylcholine (ACh) is the principal neurotransmitter of the cholinergic system, with central roles in attention, working memory, declarative learning, and the consolidation of long-term memory. The cholinergic projections from the basal forebrain (nucleus basalis of Meynert, medial septum) to the cortex and hippocampus are among the earliest neural systems to degenerate in Alzheimer's disease, and the resulting cholinergic deficit is widely accepted as a major driver of the early cognitive symptoms.
The functional concentration of acetylcholine in cholinergic synapses depends on the balance between two processes:
- Acetylcholine synthesis and release — the presynaptic enzyme choline acetyltransferase (ChAT) synthesizes ACh from choline and acetyl-CoA, and the neurotransmitter is released into the synaptic cleft on neuronal firing
- Acetylcholine catabolism — acetylcholinesterase (AChE) is the synaptic enzyme that hydrolyzes ACh to choline and acetate, terminating the synaptic signal. AChE is one of the fastest enzymes known — it can catabolize 25,000 ACh molecules per second per active site.
Inhibiting AChE slows the catabolism, raising the standing concentration of ACh in the synapse and prolonging the duration of cholinergic signaling. This is the principal mechanism of all four U.S. Food and Drug Administration-approved Alzheimer's cholinesterase inhibitors:
- Donepezil — selective AChE inhibitor, the most-prescribed cholinesterase inhibitor in the United States
- Rivastigmine — dual AChE and butyrylcholinesterase inhibitor; available as oral capsule and transdermal patch
- Galantamine — AChE inhibitor that also has nicotinic acetylcholine receptor allosteric modulation; originally isolated from snowdrop (Galanthus) and daffodil (Narcissus)
- Tacrine — the first AChE inhibitor approved for Alzheimer's; withdrawn from the US market due to hepatotoxicity
Some lemon balm preparations inhibit AChE in the test tube. Dastmalchi and colleagues (2009) found that a lemon balm extract inhibited the enzyme in a time- and dose-dependent manner, and that its most potent fraction contained cis- and trans-rosmarinic acid and a rosmarinic acid derivative. Ferreira and colleagues (2006) found AChE inhibitory capacity higher than 50% in the essential oil fraction of lemon balm. But the screening done for the Kennedy 2003 trial found no cholinesterase inhibitory properties in the dried leaf used in that trial, which acted on nicotinic and muscarinic receptors instead. The potency of any lemon balm extract is far lower than that of donepezil (a designed pharmaceutical optimized for potent AChE inhibition), and which of these mechanisms, if any, produces the cognitive effects seen in people is not known.
Nicotinic and Muscarinic Receptor Binding
Beyond AChE inhibition, lemon balm extracts have demonstrated direct binding affinity for both classes of cholinergic receptor:
- Muscarinic acetylcholine receptors (mAChRs) — G-protein-coupled receptors with five subtypes (M1-M5). M1 receptors in the cortex and hippocampus are particularly important for declarative memory. Lemon balm extract displaces radiolabeled muscarinic ligands in binding assays on human cortex tissue, with the activity concentrated in the more polar fractions.
- Nicotinic acetylcholine receptors (nAChRs) — ligand-gated ion channels with many subunit combinations. The alpha-7 subtype is implicated in attention and the alpha-4-beta-2 subtype in working memory. Lemon balm extract also displaces radiolabeled nicotinic ligands, again with the activity in the more polar fractions.
Receptor binding combined with the AChE inhibition seen in some extracts would give lemon balm a multi-point cholinergic enhancement profile that may explain why the clinical effects on cognition appear larger than would be predicted from the modest AChE inhibition alone. The combination is at least theoretically more pharmacologically interesting than the single-mechanism AChE inhibition of donepezil — it more closely resembles galantamine, which combines AChE inhibition with nicotinic receptor allosteric modulation.
Akhondzadeh 2003: Lemon Balm in Mild-to-Moderate Alzheimer's
The pivotal clinical trial demonstrating lemon balm's effect in actual Alzheimer's disease was published by Shahin Akhondzadeh and colleagues at the Roozbeh Psychiatric Hospital and Tehran University of Medical Sciences in 2003 (Journal of Neurology, Neurosurgery and Psychiatry). The study was a 16-week double-blind, parallel-group, placebo-controlled, randomized clinical trial in 42 patients (18 women, 24 men) aged 65 to 80 with mild-to-moderate Alzheimer's disease (AD), a score of 12 or more on the ADAS-cog and 2 or less on the Clinical Dementia Rating, run at three centres in Tehran.
Patients were randomized to a fixed dose of Melissa officinalis extract, 60 drops daily, or placebo for 16 weeks. Outcome measures at baseline, week 8, and week 16 were:
- Alzheimer's Disease Assessment Scale — cognitive subscale (ADAS-cog) — the standard cognitive endpoint in AD clinical trials
- Clinical Dementia Rating — sum of boxes (CDR-SB) — a structured clinical interview measuring cognitive and functional dementia severity
- Safety monitoring — side effects systematically recorded
Results at week 16:
- Lemon balm group showed statistically significant improvement on ADAS-cog compared to placebo (p = 0.01)
- Lemon balm group showed statistically significant improvement on CDR-SB compared to placebo (p < 0.0001)
- The effect size was modest but clinically meaningful — smaller than donepezil in head-to-head trials would be expected to show but in the same general magnitude
- Adverse events were minimal and not significantly different between groups; one notable observation was that agitation was significantly less common in the lemon balm group than the placebo group (p = 0.03), consistent with the herb's known anxiolytic effect
This trial is the principal evidence supporting clinical use of lemon balm in mild-to-moderate Alzheimer's. It was run at three centres with a modest sample size (42 patients) and a non-pharmaceutical-quality standardized extract, but the design is rigorous and the results are coherent with the mechanistic data from Kennedy.
A later placebo-controlled trial did not reproduce the cognitive result. In a 2020 Japanese 24-week double-blind trial (Noguchi-Shinohara and colleagues), 23 patients with mild dementia due to Alzheimer's disease took either placebo or a lemon balm extract giving 500 mg of rosmarinic acid a day. The extract was safe and well tolerated, with no serious adverse events, but there were no significant differences in cognitive measures. The Neuropsychiatric Inventory Questionnaire (NPI-Q) score, which tracks behaviour and mood symptoms, improved by 0.5 points on the extract and worsened by 0.7 points on placebo (P = 0.012), and no significant differences were seen in disease-related biomarkers.
A companion study from the same Iranian group, published earlier in 2003 in the Journal of Clinical Pharmacy and Therapeutics, found that Salvia officinalis (sage) extract (60 drops a day for 4 months, 42 patients) produced a significantly better outcome on cognitive function than placebo in mild-to-moderate AD — reinforcing the conclusion that the cognitive effect is a class effect of the Lamiaceae phenolic-rich herbs, not specific to lemon balm.
Lemon Balm vs Donepezil, Rivastigmine, Galantamine
The cholinesterase inhibitors used in conventional Alzheimer's care are modestly effective drugs — the typical effect size in 6-month clinical trials is approximately a 2-3 point improvement on the 70-point ADAS-cog scale (a 2006 Cochrane review of 13 randomized, double-blind, placebo-controlled trials of donepezil, galantamine or rivastigmine found an average of -2.7 points, 95% CI -3.0 to -2.3, and noted that none of the treatment effects are large) and a 1.5-2 point improvement on the 40-item Severe Impairment Battery in moderate-severe AD. The benefit translates to a delay of cognitive decline of approximately 6-9 months in responders, with no impact on disease modification or eventual outcomes.
Compared to prescription cholinesterase inhibitors, lemon balm:
- Has a smaller documented effect size — the Akhondzadeh AD trial effect was meaningful but smaller than typical donepezil trials would show
- Has a far cleaner side-effect profile — the gastrointestinal side effects of cholinesterase inhibitors (nausea, vomiting, diarrhea, anorexia) are prominent: in the 2006 Cochrane review approximately 29% of treated patients left trials on account of adverse events, against 18% on placebo, and nausea, vomiting and diarrhoea were significantly more frequent than on placebo; rivastigmine gastrointestinal (GI) side effects are even worse and led to the patch formulation; lemon balm side effects are minimal
- Adds anxiolytic and sleep benefit — donepezil has no significant anxiolytic effect and may actually disrupt sleep architecture (vivid dreams, insomnia in some patients); lemon balm produces the additional anxiolytic and sleep benefit relevant to many AD patients
- Costs far less — the annual cost of a clinical lemon balm regimen is approximately 50-200 USD; the annual cost of donepezil before generic versions was several thousand USD at insurance copays (generic donepezil is now reasonable cost-wise)
- Is not a substitute for prescription care in moderate-to-severe AD — the trial evidence is in mild-to-moderate disease, and it does not show lemon balm to be equivalent to standard cholinesterase inhibitor therapy in established AD
Lemon balm has been discussed in three roles: as an adjunct to standard care, as an option for people who cannot tolerate the gastrointestinal side effects of cholinesterase inhibitors, and as a botanical option in very early mild cognitive impairment, where prescription cholinesterase inhibitors are not yet typically started. The trials do not show it replacing prescription AD therapy for people who tolerate and benefit from those drugs.
The combination of lemon balm with a prescription cholinesterase inhibitor is pharmacologically rational (both raise cholinergic tone, by complementary mechanisms) but adds risk of additive cholinergic side effects (nausea, diarrhea, vivid dreams, urinary urgency).
The Lamiaceae Cognitive Family (Sage, Rosemary, Spearmint)
Lemon balm is one member of a family of cognitively active Lamiaceae herbs that share substantial chemistry and overlapping mechanisms:
- Sage (Salvia officinalis and Salvia lavandulaefolia) — the most-studied cognitive Lamiaceae after lemon balm. Akhondzadeh 2003 trial in AD; Tildesley 2003 and 2005 healthy-volunteer cognitive enhancement trials from Kennedy's group. AChE inhibition is more potent than lemon balm. See Sage.
- Rosemary (Rosmarinus officinalis) — the herb that gave rosmarinic acid its name (it was first isolated from rosemary). Cognitive enhancement evidence in healthy volunteers (Moss 2003 aromatherapy trials), modest evidence in mild cognitive impairment. See Rosemary.
- Spearmint (Mentha spicata) — a standardized aqueous spearmint extract has positive cognitive enhancement randomized controlled trials (RCTs) in healthy older adults. Mechanism involves rosmarinic acid and salvianolic acid.
- Peppermint (Mentha × piperita) — aroma-based cognitive enhancement evidence (alertness, focus), less direct AChE evidence than the others. See Peppermint.
- Oregano, thyme, basil, marjoram — all share the rosmarinic acid backbone; cognitive effects are presumed but less directly studied.
The shared chemistry suggests that broad culinary use of multiple Lamiaceae herbs may contribute to dietary cognitive support, consistent with the Mediterranean diet's observational association with reduced dementia risk. For targeted cognitive enhancement, lemon balm and sage have the strongest individual evidence; rosemary and spearmint have meaningful supporting evidence.
Mild Cognitive Impairment Applications
Mild cognitive impairment (MCI) is the diagnostic intermediate between normal age-related cognitive change and dementia. Patients with MCI have objective cognitive decline (typically on memory testing) that exceeds age expectations but do not meet functional criteria for dementia — they can still manage their finances, medications, and daily activities independently. Approximately 10-15% of MCI patients progress to dementia per year, but a substantial fraction remain stable or even improve.
Prescription cholinesterase inhibitors are not typically initiated in MCI — the trials in MCI populations have shown modest or no benefit on conversion to AD, and the side-effect burden is not justified by the marginal effect. This leaves a clinical gap: a patient with objective MCI who is concerned about cognitive trajectory and wants to do something, but for whom prescription therapy is not indicated.
Lemon balm has been proposed for this gap. The cognitive results of the Kennedy healthy-volunteer trials and the Akhondzadeh mild-AD trial support the hypothesis that lemon balm could be useful at the MCI stage, although the 2020 trial in mild Alzheimer's dementia found no difference in cognitive measures. The lifestyle-modification character of an herbal regimen (typically combined with sleep hygiene, exercise, Mediterranean-pattern diet, social engagement, cognitive activity) aligns with the broader multimodal intervention approach that has the best supporting evidence for delaying progression of MCI.
Practitioner regimens for mild cognitive impairment that include lemon balm typically combine:
- Standardized lemon balm extract 300-600 mg twice daily, or equivalent tea/tincture (the trials used single doses of 300 mg to 1600 mg in healthy volunteers and a fixed 60 drops a day in mild-to-moderate AD)
- Vitamin D3 repletion, with serum 25-hydroxyvitamin D (25(OH)D) targets of 40-60 ng/mL in those regimens
- B12 assessment and repletion when deficient (low B12 is reversibly associated with cognitive impairment)
- Omega-3 fatty acids (eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) combined approximately 1,000-2,000 mg/day in those regimens)
- Daily aerobic exercise (described as the single best-evidenced lifestyle intervention for MCI)
- Mediterranean-pattern diet and good sleep
- Periodic cognitive assessment (Montreal Cognitive Assessment (MoCA) every 6-12 months) to follow the trajectory
- Prescription cholinesterase inhibitors as the next step if progression to AD becomes evident
Combining Lemon Balm with Conventional Care
For people with established mild-to-moderate AD already on a prescription cholinesterase inhibitor, practitioners who add lemon balm as an adjunct describe these points, most of them about the additive cholinergic potential:
- Low starting dose — practitioner regimens begin at 300 mg standardized extract once daily, in the evening, for the first 2 weeks
- Gastrointestinal side effects — nausea, diarrhea and urinary urgency are the possible additive effects; practitioners lower the dose when they appear
- Anxiolytic and sleep effects — many people with AD have evening agitation ("sundowning"), sleep disturbance, and anxiety that fall outside the cholinergic-only mechanism of donepezil; lemon balm's calming effect is aimed at these, and agitation was less common on lemon balm than on placebo in the Akhondzadeh trial (p = 0.03)
- Heart rate — cholinergic effects can additively slow heart rate, which matters most for people also taking medicines that slow the heart
- Cholinesterase-inhibitor intolerance — when someone cannot tolerate donepezil's gastrointestinal side effects but the family wants to continue some form of cholinergic intervention, lemon balm has been used as a substitute
For people on memantine (an N-methyl-D-aspartate (NMDA) receptor antagonist used in moderate-severe AD), the mechanisms of the two do not overlap.
Dosing for Cognitive Indications
- Standardized extract for cognitive enhancement — the Kennedy trials used single doses of 300, 600 and 900 mg of a standardized extract (2002), 600, 1000 and 1600 mg of dried leaf (2003) and 300 and 600 mg of a standardized extract (2004); clinical practice typically uses 300 mg twice daily (600 mg/day total) for chronic cognitive use. In the 2003 trial the highest dose (1600 mg) gave the clearest memory and calmness results, while in the 2002 trial alertness was significantly reduced after the highest dose (900 mg).
- Standardized extract for mild-to-moderate Alzheimer's — Akhondzadeh protocol was a fixed dose of 60 drops of extract daily; the 2020 Japanese trial used an extract giving 500 mg of rosmarinic acid a day. Most current clinical practice uses 600 mg/day of a high-rosmarinic-acid standardized extract.
- Tea — 1-2 teaspoons of dried herb (or 1 tablespoon fresh) steeped covered for 10-15 minutes, 2-3 cups daily. Less reliable for cognitive indications than standardized extract because rosmarinic acid extraction in tea is incomplete.
- Tincture — 2-4 mL of 1:5 hydroalcoholic tincture twice daily.
- Timing — morning and afternoon doses are used for cognitive enhancement, and an evening dose when sleep onset is a secondary goal.
- Duration — the cognitive benefits in the Kennedy trials are evident from the first dose; the AD benefits in the Akhondzadeh trial accumulate over 8-16 weeks. For chronic cognitive support, practitioners describe 4-8 weeks of consistent use before the effect is judged.
Cautions and Drug Interactions
- Additive cholinergic effects with prescription AChE inhibitors — nausea, diarrhea, urinary urgency, bradycardia can be additively worsened.
- Bradycardia-prone patients — AChE inhibition mildly slows heart rate, an added concern for people on beta-blockers, calcium channel blockers (especially verapamil, diltiazem), digoxin, or with sick sinus syndrome.
- Anticholinergic medications — lemon balm partially opposes the cognitive effects of anticholinergic drugs (diphenhydramine, tricyclic antidepressants, oxybutynin, scopolamine). This is generally beneficial — anticholinergic medications worsen dementia and the partial opposition is desirable — but the drug doses may need adjustment.
- Additive sedation with GABAergic drugs — as discussed in the Anxiety Relief page.
- Thyroid function — the concern applies to people on thyroid hormone replacement using chronic high-dose lemon balm; thyroid-stimulating hormone (TSH) is the blood test that tracks thyroid function.
- Pregnancy and lactation — not formally cleared for chronic high-dose use.
- Dementia-related driving safety — in patients with cognitive impairment severe enough to raise driving concerns, lemon balm does not worsen driving capacity but also does not adequately address the underlying impairment. Driving fitness depends on the underlying impairment, which herbal therapy does not change.
Key Research Papers
- Kennedy DO, Scholey AB, Tildesley NT, Perry EK, Wesnes KA (2002). Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacology Biochemistry and Behavior. 72(4):953-64. — PubMed PMID: 12062586
- Kennedy DO, Wake G, Savelev S, Tildesley NT, Perry EK, Wesnes KA, Scholey AB (2003). Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. Neuropsychopharmacology. 28(10):1871-81. — PubMed PMID: 12888775
- Kennedy DO, Little W, Scholey AB (2004). Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (Lemon Balm). Psychosomatic Medicine. 66(4):607-13. — PubMed PMID: 15272110
- Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M (2003). Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial. Journal of Neurology, Neurosurgery and Psychiatry. 74(7):863-6. — PubMed PMID: 12810768
- Noguchi-Shinohara M, Ono K, Hamaguchi T, Nagai T, Kobayashi S, Komatsu J, Samuraki-Yokohama M, Iwasa K, Yokoyama K, Nakamura H, Yamada M (2020). Safety and efficacy of Melissa officinalis extract containing rosmarinic acid in the prevention of Alzheimer's disease progression. Scientific Reports. 10(1):18627. — PubMed PMID: 33122694
- Wake G, Court J, Pickering A, Lewis R, Wilkins R, Perry E (2000). CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. Journal of Ethnopharmacology. 69(2):105-14. — PubMed PMID: 10687867
- Dastmalchi K, Ollilainen V, Lackman P, Boije af Gennäs G, Dorman HJ, Järvinen PP, Yli-Kauhaluoma J, Hiltunen R (2009). Acetylcholinesterase inhibitory guided fractionation of Melissa officinalis L. Bioorganic and Medicinal Chemistry. 17(2):867-71. — PubMed PMID: 19070498
- Ferreira A, Proença C, Serralheiro ML, Araújo ME (2006). The in vitro screening for acetylcholinesterase inhibition and antioxidant activity of medicinal plants from Portugal. Journal of Ethnopharmacology. 108(1):31-7. — PubMed PMID: 16737790
- Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M (2003). Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. 28(1):53-9. — PubMed PMID: 12605619
- Tildesley NT, Kennedy DO, Perry EK, Ballard CG, Savelev S, Wesnes KA, Scholey AB (2003). Salvia lavandulaefolia (Spanish sage) enhances memory in healthy young volunteers. Pharmacology Biochemistry and Behavior. 75(3):669-74. — PubMed PMID: 12895685
- Kennedy DO, Scholey AB (2006). The psychopharmacology of European herbs with cognition-enhancing properties. Current Pharmaceutical Design. 12(35):4613-23. — PubMed PMID: 17168769
- Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NS (1999). Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. Journal of Pharmacy and Pharmacology. 51(5):527-34. — PubMed PMID: 10411211
- Howes MJ, Houghton PJ (2003). Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacology Biochemistry and Behavior. 75(3):513-27. — PubMed PMID: 12895669
- Birks J (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews. 2006(1):CD005593. — PubMed PMID: 16437532
- Ferris S, Karantzoulis S, Somogyi M, Meng X (2013). Rivastigmine in moderately severe-to-severe Alzheimer's disease: Severe Impairment Battery factor analysis. Alzheimer's Research and Therapy. 5(6):63. — PubMed PMID: 24351447
- Ozarowski M, Mikolajczak PL, Bogacz A, Gryszczynska A, Kujawska M, Jodynis-Liebert J, et al. (2013). Rosmarinus officinalis L. leaf extract improves memory impairment and affects acetylcholinesterase and butyrylcholinesterase activities in rat brain. Fitoterapia. 91:261-271. — PubMed PMID: 24080468
- Shakeri A, Sahebkar A, Javadi B (2016). Melissa officinalis L. - A review of its traditional uses, phytochemistry and pharmacology. Journal of Ethnopharmacology. 188:204-28. — PubMed PMID: 27167460